Physician profile
John T Cates
NPI 1467424176
$1,236.94
in general payments reported to CMS, 2019-2025
20 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.18 · 2020: $86.50 · 2021: $187 · 2022: $214 · 2023: $173 · 2024: $125 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643 · Entertainment: $16.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.92 |
| Entertainment | $16.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $274.16 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $192.41 | 2019-2025 | Tryptyr, Precision7 |
| Tarsus Pharmaceuticals, INC. | $166.93 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $87.13 | 2021-2022 | |
| Abbvie INC. | $81.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $67.76 | 2019-2023 | |
| Oyster Point Pharma, INC. | $63.30 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $56.07 | 2024-2025 | Infuse, Biotrue One Day, Biotrue |
| Sun Pharmaceutical Industries INC. | $34.28 | 2023-2025 | Cequa |
| Amgen INC. | $28.67 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $23.88 | 2023 | Tepezza |
| Optos, INC. | $23.31 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Maculogix, INC. | $23.15 | 2021 | |
| Harrow Eye, LLC | $20.33 | 2025 | Vevye |
| Lkc Technologies, INC. | $18.21 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $17.07 | 2021 | |
| Dompe US, INC. | $16.10 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.81 | 2020 | |
| Biotissue Holdings INC. | $13.95 | 2019 | |
| Shire North American Group INC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.